购物车
- 全部删除
- 您的购物车当前为空
Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).
Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 824 | 5日内发货 | |
5 mg | ¥ 1,410 | 5日内发货 | |
25 mg | ¥ 4,800 | 8-10周 | |
50 mg | ¥ 6,240 | 8-10周 | |
100 mg | ¥ 9,620 | 8-10周 |
产品描述 | Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively). |
靶点活性 | ERK2:3.1 nM, p-RSK:12 nM, ERK1:6.1 nM |
体外活性 | Ravoxertinib inhibits p90RSK (IC50: 12 nM) [1]. Ravoxertinib is highly selective for ERK1 and ERK2 (biochemical potency: 1.1 nM and 0.3 nM, respectively) [2]. |
体内活性 | Ravoxertinib (10 mg/kg; p.o.; in CD-1 mice) is sufficient to achieve the desired target coverage for at least 8 h [1]. Ravoxertinib (p.o.; daily) causes significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice [2]. |
别名 | GDC-0994 (hydrochloride) |
分子量 | 477.32 |
分子式 | C21H19Cl2FN6O2 |
CAS No. | 2070009-58-2 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 100 mg/mL (209.50 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容